Feb 26, 2026 07:00AM
Oct 30, 2025 07:00AM
Jul 31, 2025 07:00AM
Jun 24, 2025 04:13PM
Jun 24, 2025 04:12PM
Oct 31, 2023 09:00AM
May 22, 2023 07:40PM Indivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl
Mar 2, 2023 10:14AM
Feb 7, 2023 04:02PM
Feb 7, 2023 04:01PM
Feb 6, 2023 08:00AM
Dec 7, 2022 02:30AM
Nov 20, 2022 08:46AM
Nov 14, 2022 02:12AM Indivior PLC to Acquire Opiant Pharmaceuticals
Nov 14, 2022 02:10AM
Jul 24, 2020 10:35AM
Jun 24, 2020 08:30AM
Mar 23, 2020 08:00AM
Dec 10, 2019 09:30AM
Dec 2, 2019 08:00AM
Nov 11, 2019 12:43PM Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can "Keep Moving Towards Recovery"
Sep 26, 2019 03:19PM
Jun 17, 2019 02:43PM
Apr 9, 2019 06:01PM
Apr 6, 2019 08:36AM
Apr 5, 2019 08:36AM
Mar 7, 2019 10:30AM
Feb 27, 2019 08:06AM Indivior Announces Launch of PERSERIS™ (risperidone) for the Treatment of Schizophrenia in Adults
Feb 20, 2019 09:37AM
Feb 19, 2019 08:00AM
Dec 20, 2018 09:00AM
Nov 27, 2018 08:00AM
Nov 23, 2018 09:56AM
Nov 21, 2018 09:30AM
Nov 19, 2018 08:06AM PERSERIS™, the First Once-Monthly Risperidone-Containing Subcutaneous Long-Acting Injectable, Now Available in the U.S. for the Treatment of Schizophrenia in Adults
Nov 1, 2018 07:26AM
Oct 24, 2018 02:32PM
Sep 26, 2018 11:57AM
Jul 31, 2018 08:03AM
Jul 27, 2018 07:44PM
Jul 13, 2018 06:22PM
Jul 11, 2018 07:47AM Indivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous Expectations
Jun 28, 2018 06:07PM
Jun 15, 2018 08:00PM
Jun 15, 2018 10:11AM
May 31, 2018 08:45AM
May 25, 2018 09:55AM
Apr 20, 2018 09:00AM
Apr 13, 2018 11:44AM Patient-Reported Outcomes Data on SUBLOCADE™ (Buprenorphine Extended-Release) Injection to be Presented as Late-Breaker at American Society of Addiction Medicine (ASAM) 49th Annual Conference
Mar 29, 2018 08:00AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All